HC Wainwright Expects Stronger Earnings for DBV Technologies

DBV Technologies S.A. (NASDAQ:DBVT) – Equities researchers at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of DBV Technologies in a research report issued to clients and investors on Monday, December 15th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($1.85) per share for the year, up from their previous forecast of ($5.45). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2027 earnings at ($1.55) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at $1.80 EPS.

DBVT has been the topic of a number of other reports. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research note on Wednesday. Citizens Jmp upped their price target on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday. Guggenheim reissued a “buy” rating and issued a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Finally, Cantor Fitzgerald raised DBV Technologies to a “strong-buy” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.54.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT opened at $17.98 on Wednesday. The stock has a market capitalization of $722.08 million, a P/E ratio of -3.48 and a beta of -1.10. The stock’s fifty day moving average is $14.98 and its 200 day moving average is $11.58. DBV Technologies has a 52 week low of $2.74 and a 52 week high of $21.50.

Hedge Funds Weigh In On DBV Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vivo Capital LLC bought a new stake in shares of DBV Technologies during the second quarter worth $9,659,000. Nan Fung Trinity HK Ltd. acquired a new stake in shares of DBV Technologies during the 2nd quarter valued at $340,000. Adage Capital Partners GP L.L.C. bought a new stake in DBV Technologies during the 2nd quarter worth $9,659,000. MPM Bioimpact LLC bought a new stake in DBV Technologies during the 2nd quarter worth $9,649,000. Finally, Octagon Capital Advisors LP acquired a new position in DBV Technologies in the 2nd quarter worth about $9,315,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.